TP015/#1539 A double-blind, placebo-controlled, phase II chemoimmunotherapy (Paclitaxel-carboplatin...
TP015/#1539 A double-blind, placebo-controlled, phase II chemoimmunotherapy (Paclitaxel-carboplatin-oregovomab) vs chemotherapy (Paclitaxel-carboplatin-placebo) as neoadjuvant therapy in patients with advanced epithelial ovarian, fallopian tube or peritoneal carcinoma
About this item
Full title
Author / Creator
Publisher
Kidlington: BMJ Publishing Group Ltd
Journal title
Language
English
Formats
Publication information
Publisher
Kidlington: BMJ Publishing Group Ltd
Subjects
More information
Scope and Contents
Contents
IntroductionOregovomab, a murine IgGκ monoclonal antibody binds to tumor-associated antigen, CA125, rendering target antigen CA125 more immunogenic through enhanced antigen processing and presentation to specific T cells, bypassing tumor-associated suppression and resulting in enhanced efficacy of chemotherapy. In a randomized phase II study, orego...
Alternative Titles
Full title
TP015/#1539 A double-blind, placebo-controlled, phase II chemoimmunotherapy (Paclitaxel-carboplatin-oregovomab) vs chemotherapy (Paclitaxel-carboplatin-placebo) as neoadjuvant therapy in patients with advanced epithelial ovarian, fallopian tube or peritoneal carcinoma
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_proquest_journals_2887566085
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_proquest_journals_2887566085
Other Identifiers
ISSN
1048-891X
E-ISSN
1525-1438
DOI
10.1136/ijgc-2023-IGCS.475
